Quantum BioPharma Receives FDA Approval for MS Drug Trial

NEW YORK, Sept. 11, 2026 /CourierPR/ -- Quantum BioPharma Ltd., a biopharmaceutical company based in the United States, has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class drug designed to shield and potentially rebuild the myelin sheath in patients with multiple sclerosis (MS). This development marks a significant milestone in the treatment of MS, a condition that affects nearly 2.9 million people worldwide and nearly a million in the United States alone.

Currently, MS treatments can slow disease progression but do not halt it entirely. They also fail to restore lost functions, leaving patients with ongoing challenges in mobility, eyesight, and physical control. Lucid-MS, developed by Quantum BioPharma, aims to address this gap by targeting the underlying mechanism of MS, myelin degradation. The drug is based on a patented new chemical entity that has shown promise in preclinical models.

The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., is responsible for the research and development of Lucid-MS. This drug is part of Quantum BioPharma's broader portfolio, which includes innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The phase 2 trial will be the first time a drug built on this exact mechanism is tested in people living with MS, potentially offering a new approach to the disease.

The clearance from the FDA sets the stage for what could be a transformative moment in MS treatment. Wall Street analysts have already responded positively, issuing a fresh buy rating for Quantum BioPharma. This recognition underscores the potential of Lucid-MS to reshape the multibillion-dollar therapeutics market for MS.

Quantum BioPharma's commitment to developing groundbreaking treatments for MS is evident in its approach. The company's lead compound, Lucid-MS, is designed to not only slow the progression of the disease but also potentially reverse the damage caused by myelin degradation. This dual approach could offer patients a more comprehensive treatment option, addressing both the symptoms and the root cause of the condition.

The company's strategy also includes a partnership with Unbuzzd Wellness Inc., a subsidiary focused on the development of consumer products. Quantum retains a significant stake in Unbuzzd and receives royalty payments from the sale of unbuzzd products, which are based on the company's proprietary technology. This dual focus on pharmaceutical and consumer products highlights Quantum BioPharma's commitment to diversifying its revenue streams while advancing its core mission of treating challenging neurological conditions.

In summary, Quantum BioPharma Ltd.'s FDA clearance to launch a phase 2 trial of Lucid-MS represents a significant step forward in the treatment of multiple sclerosis. This development could provide much-needed relief to millions of patients worldwide and potentially redefine the landscape of MS therapeutics.